Yonsei Med J.  2001 Jun;42(3):278-284. 10.3349/ymj.2001.42.3.278.

Primary Humoral Immune Responses to Formalin Inactivated Hemorrhagic Fever with Renal Syndrome Vaccine (Hantavax(R)): Consideration of Active Immunization in South Korea

Affiliations
  • 1Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea. youngmo@yumc.yonsei.ac.kr
  • 2Department of Epidemiology, Graduate School of Public Health, Seoul National University, Korea.
  • 3Virology Department, United States Army Medical Research Institute of Infectious Disease, Currently, Division of Clinical Laboratory Devices, Center for Devices & Radiological Health, Food and Drug Administration, Rockville, MD, USA.

Abstract

The efficacy of a formalin-inactivated hemorrhagic fever with renal syndrome (HFRS) vaccine and the effectiveness of a related vaccination program have not been previously evaluated. We measured the primary immune responses to Hantavax by plaque reduction neutralizing antibody test (PRNT), hemagglutination inhibition test (HAI), ELISA and high density particle agglutination test (HDPA) in order to confirm a possible biological efficacy through independent substantiation of experimental results and to compare the results with previous studies. Following two doses of primary vaccination, the seroconversion rate of PRNT and HAI antibody was 33.3% (10/30)[95% C.I. 17.3-52.5%] and 26.7% (8/30) [95% C.I. 12.3-45.9%], respectively. The correlation between PRNT and HAI antibody showed a statistical significance (r=0.58, p 0.01). The seroconversion rate of HDPA and ELISA were both 76.7% (23/30) [95% C.I. 57.7-90.1%], which correlated well with each other(r=0.58, p 0.01). In our study, Hantavax elicited low neutralizing antibody responses, at least in the volunteers samples that we tested. The vaccination program, including the vaccine itself, that has been adopted by the national immunization program to protect against HFRS in Korea should be re-evaluated and re-formulated to produce a higher protective immune response rate.

Keyword

Hemorrhagic fever with renal syndrome; vaccine; immunogenicity; neutralizing antibody; vaccination policy

MeSH Terms

Adult
Antibodies, Viral/*blood
Hantaan Virus/*immunology
Human
IgG/blood
Korea
Middle Age
Time Factors
Vaccination
Vaccines, Attenuated/immunology
Viral Vaccines/*immunology

Cited by  4 articles

Epidemiology of Hemorrhagic Fever with Renal Syndrome in Endemic Area of the Republic of Korea, 1995-1998
Joon Young Song, Byung Chul Chun, Soon Duck Kim, Luck Ju Baek, Sang-Hoon Kim, Jang Wook Sohn, Hee Jin Cheong, Woo Joo Kim, Seung Chul Park, Min Ja Kim
J Korean Med Sci. 2006;21(4):614-620.    doi: 10.3346/jkms.2006.21.4.614.

Toxic Epidermal Necrolysis with Ocular Involvement Following Vaccination for Hemorrhagic Fever with Renal Syndrome
Young Hoon Hwang, Myung Seung Kang, Kyung O Lim, Sang Mok Lee
Yonsei Med J. 2012;53(1):228-230.    doi: 10.3349/ymj.2012.53.1.228.

Hemorrhagic Fever with Renal Syndrome
Hyo Youl Kim
Infect Chemother. 2009;41(6):323-332.    doi: 10.3947/ic.2009.41.6.323.

Milestones in history of adult vaccination in Korea
Myoung-don Oh, Jong-Koo Lee
Clin Exp Vaccine Res. 2012;1(1):9-17.    doi: 10.7774/cevr.2012.1.1.9.

Full Text Links
  • YMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr